Back to mobile site

RBC Capital on Nurix (NRIX): 'Execution in CLL Remains Key'

April 9, 2026 8:34 AM EDT Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $30.00 price target on Nurix (NASDAQ: NRIX).The analyst commented: "Execution ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login